Literature DB >> 15466383

Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.

Ramesh Prabhu1, Nutan Khalap, Roberto Burioni, Massimo Clementi, Robert F Garry, Srikanta Dash.   

Abstract

Hepatitis C virus (HCV) nonstructural protein 3 (NS3), with its protease, helicase, and NTPase enzymatic activities, plays a crucial role in viral replication, and therefore represents an ideal target for the development of anti-viral agents. We have developed a recombinant human antibody (Fab) that reacts with the helicase domain of HCV NS3. The affinity-purified Fab antibody completely inhibited the helicase activity of HCV NS3 at equimolar concentration. To evaluate the effect of the Fab on HCV replication, the clone encoding the Fab gene was put into an expression vector, which converts Fab into a complete IgG1 antibody. Using a DNA-based transfection model, we demonstrated that intracellular expression of this antibody resulted in significant reduction of HCV-negative strand RNA synthesis. Intracellular expression of this antibody into either a stable cell line replicating subgenomic RNA, or a transient full-length HCV replication model, reduced both HCV RNA and viral protein expression. These results support the use of recombinant antibody fragments to inhibit NS3 enzyme as a novel, feasible, and effective approach for inhibiting HCV replication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466383      PMCID: PMC1618619          DOI: 10.1016/S0002-9440(10)63377-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.

Authors:  T Ueno; S Misawa; Y Ohba; M Matsumoto; M Mizunuma; N Kasai; K Tsumoto; I Kumagai; H Hayashi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization.

Authors:  P Steinberger; J K Sutton; C Rader; M Elia; C F Barbas
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

3.  Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.

Authors:  D G Macejak; K L Jensen; S F Jamison; K Domenico; E C Roberts; N Chaudhary; I von Carlowitz; L Bellon; M J Tong; A Conrad; P A Pavco; L M Blatt
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

Review 4.  Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS.

Authors:  W A Marasco; J LaVecchio; A Winkler
Journal:  J Immunol Methods       Date:  1999-12-10       Impact factor: 2.303

5.  Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease.

Authors:  M Oketani; Y Asahina; C H Wu; G Y Wu
Journal:  J Hepatol       Date:  1999-10       Impact factor: 25.083

6.  Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments.

Authors:  R Burioni; P Plaisant; A Manzin; D Rosa; V Delli Carri; F Bugli; L Solforosi; S Abrignani; P E Varaldo; G Fadda; M Clementi
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

7.  HCV RNA levels in hepatocellular carcinomas and adjacent non-tumorous livers.

Authors:  S Dash; R Saxena; J Myung; T Rege; H Tsuji; P Gaglio; R F Garry; S N Thung; M A Gerber
Journal:  J Virol Methods       Date:  2000-10       Impact factor: 2.014

Review 8.  The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy.

Authors:  R Bartenschlager
Journal:  J Viral Hepat       Date:  1999-05       Impact factor: 3.728

9.  Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial.

Authors:  M Eddleston; S Rajapakse; S Jayalath; L Sjöström; W Santharaj; P N Thenabadu; M H Sheriff; D A Warrell
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

10.  Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo.

Authors:  A A Kolykhalov; K Mihalik; S M Feinstone; C M Rice
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

View more
  17 in total

Review 1.  Understanding helicases as a means of virus control.

Authors:  D N Frick; A M I Lam
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

2.  Single strand binding proteins increase the processivity of DNA unwinding by the hepatitis C virus helicase.

Authors:  Vaishnavi Rajagopal; Smita S Patel
Journal:  J Mol Biol       Date:  2007-11-01       Impact factor: 5.469

3.  Hepatocellular carcinoma xenograft supports HCV replication: a mouse model for evaluating antivirals.

Authors:  Sidhartha Hazari; Henry J Hefler; Partha K Chandra; Bret Poat; Feyza Gunduz; Tara Ooms; Tong Wu; Luis A Balart; Srikanta Dash
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

4.  Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Authors:  Meital Gal-Tanamy; Romy Zemel; Larissa Bachmatov; Rohit K Jangra; Assaf Shapira; Rodrigo A Villanueva; Minkyung Yi; Stanley M Lemon; Itai Benhar; Ran Tur-Kaspa
Journal:  Antiviral Res       Date:  2010-08-10       Impact factor: 5.970

5.  Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.

Authors:  Craig A Belon; David N Frick
Journal:  Future Virol       Date:  2009-05-01       Impact factor: 1.831

6.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

7.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

Review 8.  The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target.

Authors:  David N Frick
Journal:  Curr Issues Mol Biol       Date:  2007-01       Impact factor: 2.081

Review 9.  Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens.

Authors:  Nicola Clementi; Nicasio Mancini; Laura Solforosi; Matteo Castelli; Massimo Clementi; Roberto Burioni
Journal:  Int J Mol Sci       Date:  2012-07-04       Impact factor: 6.208

Review 10.  Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?

Authors:  Mancini Nicasio; Giuseppe Sautto; Nicola Clementi; Roberta A Diotti; Elena Criscuolo; Matteo Castelli; Laura Solforosi; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-09-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.